SCHEDULE 13G/A: Wellington Management Group Discloses 13.0% Passive Stake in Immunocore Holdings plc

Wellington Management Group LLP and its affiliated entities have reported a 13.0% beneficial ownership stake in Immunocore Holdings plc, held for investment purposes as of March 31, 2025.

Summary

• Wellington Management Group LLP, along with Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, collectively reported beneficial ownership of 6,430,078 shares of Immunocore Holdings plc common stock.
• This aggregate ownership represents 13.0% of Immunocore Holdings plc's outstanding common stock.
• The filing indicates that the shares are held with shared voting power of 6,247,558 shares and shared dispositive power of 6,430,078 shares.
• The reporting persons have certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Wellington Management Company LLP, an investment adviser, holds 12.7% of the class, contributing to the overall 13.0% aggregate ownership.
• The securities are owned of record by clients of the Wellington Investment Advisers, with Vanguard Health Care Fund specifically noted as a client with a right to receive dividends or proceeds from the sale of more than 5% of the class.

Sentiment

Score: 7

Explanation: The filing indicates a significant and passive institutional investment in Immunocore Holdings plc by a reputable asset manager, which is generally viewed positively as a sign of investor confidence, though it does not provide direct operational or financial performance insights from the company itself.

Positives

• The disclosure of a significant 13.0% stake by a major institutional investor like Wellington Management Group can be interpreted as a vote of confidence in Immunocore Holdings plc.
• The passive nature of the investment, as indicated by the Schedule 13G filing, suggests that Wellington Management is holding the shares for investment purposes rather than seeking to influence control, which can provide stability.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance from Immunocore Holdings plc, as it is a disclosure of beneficial ownership by an external investment group.

Industry Context

This filing highlights continued institutional investor interest in the biotechnology and pharmaceutical sector, specifically in companies like Immunocore Holdings plc. The significant stake by Wellington Management, a prominent asset manager, underscores the attractiveness of the company within the broader healthcare investment landscape.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may positively influence market perception and potentially the share price, signaling confidence from a major investor.
• Potential Investors: Provides transparency regarding the ownership structure and highlights the presence of large institutional holders, which can be a factor in investment decisions.

Key Dates

Keywords

Immunocore Holdings plc, Wellington Management Group, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, passive investment